These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 23187318)

  • 1. Anti-bacterial and anti-toxic immunity induced by a killed whole-cell-cholera toxin B subunit cholera vaccine is essential for protection against lethal bacterial infection in mouse pulmonary cholera model.
    Kang SS; Yang JS; Kim KW; Yun CH; Holmgren J; Czerkinsky C; Han SH
    Mucosal Immunol; 2013 Jul; 6(4):826-37. PubMed ID: 23187318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation into immunological responses against a native recombinant CTB whole-cell Vibrio cholerae vaccine in a rabbit model.
    Boustanshenas M; Bakhshi B; Ghorbani M
    J Appl Microbiol; 2013 Feb; 114(2):509-15. PubMed ID: 23082752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Construction of novel vaccine strains of Vibrio cholerae co-expressing the Inaba and Ogawa serotype antigens.
    Lebens M; Karlsson SL; Källgård S; Blomquist M; Ekman A; Nygren E; Holmgren J
    Vaccine; 2011 Oct; 29(43):7505-13. PubMed ID: 21807059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intranasal immunization with recombinant toxin-coregulated pilus and cholera toxin B subunit protects rabbits against Vibrio cholerae O1 challenge.
    Kundu J; Mazumder R; Srivastava R; Srivastava BS
    FEMS Immunol Med Microbiol; 2009 Jul; 56(2):179-84. PubMed ID: 19453752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Posttranslational Regulation of IL-23 Production Distinguishes the Innate Immune Responses to Live Toxigenic versus Heat-Inactivated Vibrio cholerae.
    Weil AA; Ellis CN; Debela MD; Bhuiyan TR; Rashu R; Bourque DL; Khan AI; Chowdhury F; LaRocque RC; Charles RC; Ryan ET; Calderwood SB; Qadri F; Harris JB
    mSphere; 2019 Aug; 4(4):. PubMed ID: 31434744
    [No Abstract]   [Full Text] [Related]  

  • 6. Mucosal and systemic antibody responses against an acellular pertussis vaccine in mice after intranasal co-administration with recombinant cholera toxin B subunit as an adjuvant.
    Isaka M; Yasuda Y; Taniguchi T; Kozuka S; Matano K; Maeyama J; Morokuma K; Ohkuma K; Goto N; Tochikubo K
    Vaccine; 2003 Mar; 21(11-12):1165-73. PubMed ID: 12559794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transient Intestinal Colonization by a Live-Attenuated Oral Cholera Vaccine Induces Protective Immune Responses in Streptomycin-Treated Mice.
    Fakoya B; Sit B; Waldor MK
    J Bacteriol; 2020 Nov; 202(24):. PubMed ID: 32540930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibodies and antibody-secreting cells in the female genital tract after vaginal or intranasal immunization with cholera toxin B subunit or conjugates.
    Johansson EL; Rask C; Fredriksson M; Eriksson K; Czerkinsky C; Holmgren J
    Infect Immun; 1998 Feb; 66(2):514-20. PubMed ID: 9453604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Robust gut associated vaccine-specific antibody-secreting cell responses are detected at the mucosal surface of Bangladeshi subjects after immunization with an oral killed bivalent V. cholerae O1/O139 whole cell cholera vaccine: comparison with other mucosal and systemic responses.
    Shamsuzzaman S; Ahmed T; Mannoor K; Begum YA; Bardhan PK; Sack RB; Sack DA; Svennerholm AM; Holmgren J; Qadri F
    Vaccine; 2009 Feb; 27(9):1386-92. PubMed ID: 19146897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preparation and preclinical evaluation of experimental group B streptococcus type III polysaccharide-cholera toxin B subunit conjugate vaccine for intranasal immunization.
    Shen X; Lagergård T; Yang Y; Lindblad M; Fredriksson M; Holmgren J
    Vaccine; 2000 Nov; 19(7-8):850-61. PubMed ID: 11115709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alpha-galactosylceramide enhances mucosal immunity to oral whole-cell cholera vaccines.
    Davitt CJH; Longet S; Albutti A; Aversa V; Nordqvist S; Hackett B; McEntee CP; Rosa M; Coulter IS; Lebens M; Tobias J; Holmgren J; Lavelle EC
    Mucosal Immunol; 2019 Jul; 12(4):1055-1064. PubMed ID: 30953000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The roles of mesoporous silica and carbon nanoparticles in antigen stability and intensity of immune response against recombinant subunit B of cholera toxin in a rabbit animal model.
    Karimi Bavandpour A; Bakhshi B; Najar-Peerayeh S
    Int J Pharm; 2020 Jan; 573():118868. PubMed ID: 31765785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From cholera to enterotoxigenic Escherichia coli (ETEC) vaccine development.
    Svennerholm AM
    Indian J Med Res; 2011 Feb; 133(2):188-96. PubMed ID: 21415493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholera: Immunity and Prospects in Vaccine Development.
    Harris JB
    J Infect Dis; 2018 Oct; 218(suppl_3):S141-S146. PubMed ID: 30184117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experimental immunisation and protection of guinea pigs with Vibrio cholerae toxoid and mucinases, neuraminidase and proteinase.
    Stewart-Tull DE; Lucas C; Bleakley CR
    Vaccine; 2004 Jun; 22(17-18):2137-45. PubMed ID: 15149770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholera toxin-B (ctxB) antigen expressing Salmonella Typhimurium polyvalent vaccine exerts protective immune response against Vibrio cholerae infection.
    Vishwakarma V; Sahoo SS; Das S; Ray S; Hardt WD; Suar M
    Vaccine; 2015 Apr; 33(15):1880-9. PubMed ID: 25701672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sublingual Adjuvant Delivery by a Live Attenuated Vibrio cholerae-Based Antigen Presentation Platform.
    Liao J; Gibson JA; Pickering BS; Watnick PI
    mSphere; 2018 Jun; 3(3):. PubMed ID: 29875145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Field trial of oral cholera vaccines in Bangladesh: evaluation of anti-bacterial and anti-toxic breast-milk immunity in response to ingestion of the vaccines.
    Clemens JD; Sack DA; Chakraborty J; Rao MR; Ahmed F; Harris JR; van Loon F; Khan MR; Yunis M; Huda S
    Vaccine; 1990 Oct; 8(5):469-72. PubMed ID: 2251873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infection and immunity to Vibrio cholerae, Salmonella typhimurium and Escherichia coli in a rabbit model.
    Guinée PA; Jansen WH; Rijpkema SG
    Zentralbl Bakteriol Mikrobiol Hyg A; 1988 Nov; 270(1-2):260-9. PubMed ID: 2464884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of the roles of antilipopolysaccharide and anti-cholera toxin immunoglobulin A (IgA) antibodies in protection against Vibrio cholerae and cholera toxin by use of monoclonal IgA antibodies in vivo.
    Apter FM; Michetti P; Winner LS; Mack JA; Mekalanos JJ; Neutra MR
    Infect Immun; 1993 Dec; 61(12):5279-85. PubMed ID: 8225601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.